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Abstract. Actual study proposes an actual and controversial theme in oncology, such as
expression and distribution of TNF cytokine 2-nd receptor in canine mammary cancer, and its
involvement in cancer progression and prognosis. TNFR-II was evaluated by LSAB
immunohistochemistry technique using anti-TNFR-II marker. Tumor malignancy was appreciated
using histology grading (I to III), mitotic index, nuclear grade, tumor size, and histology type. In the
study were elected benign and malign canine mammary tumors. Distribution and localization of
TNFR-II was restricted in both inflammatory cells from the sustaining stroma of studied tumors
(macrophage, lymphocyte), and in cancerous epithelial or myoepithelial cells. Obtained dates
demonstrate a direct relation between histologic grade and TNFR-II expression; TNFR-II had a lower
expression in benign and differentiated grade I canine mammary tumors (cancerous epithelial and
myoepithelial cells), and a higher expression in poorly differentiated ones (grade II cancers).
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INTRODUCTION
Mammary cancer is one of the main causes of dying in bitches having about three
folds higher incidence than breast cancer in women. We approach this type of cancer because
of its high incidence, representing the main cause of death in female dogs.
The goal of the study is to look after the distribution of the 2-nd receptor of TNFα
cytokine (TNFR-II) and interrelation (if there is one) of TNFR-II with canine mammary
cancer malignancy markers (histology grading, mitotic index, tumor size, and histology type).
The TNF (tumor necrosis factor) is a cytokine involved in immunity and inflammation, and
often presented in tumors. These active cytokines acts using tow receptors such as: TNFR-I
and TNFR-II. There are many studies involving distribution and the role of the TNFR-I. In
cancer TNFR-I mediate cytotoxic effect of TNF on tumoral cells inducing cell death or
apoptosis. Regarding TNFR-II, biologic role and its distribution in tumoral cells is still
unclear. Despite of the name seems that TNF (tumor necrosis factor) cytokine could have
carcinogenic effect respectively to initiate and favor cancer onset by involvement in chronic
inflammation, which generate increased oxidative stress known as carcinogenic agent. On the
other hand, TNF clearly possesses antitumor effects not only in preclinical models but also in
the clinical setting by inducing intratumor necrosis (Waterston Ashita et al., 2004).
MATERIALS AND METHODS
Sample harvesting, fixation, paraffin embedding, paraffined slices preparation and
staining. Mammary tumor formations had been provided by corps reached to Pathology
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department from the University of Agricultural Science and Veterinary Medicine, Faculty of
Veterinary Medicine Cluj-Napoca, Romania. There were utilized 7 malign and 2 benign
mammary tumors provided by different bitch breeds, such as: German Sheppard, Cocker
Spaniel, Stray dogs, Mioritic Sheppard, Boxer and Irish Setter. For histopathology exam the
samples had been fixed in 10% buffered formalin and processed by paraffin technique, and
stained by hematoxilin-eozin and trichrome Masson technique. The mammary tumors are
from 9 bitches, with the age of 2-13 years. To make an appropriate histology grading of
malignant tumors based on WHO classification, were evaluated nuclear degree, tubule
formation and mitotic index. Canine mammary tumors were framed in three histological
grades such as: grade I (less aggressive), grade II and grade III (high aggressivity).
Immunohistochemistry. TNFR-II and tumor proliferation were evaluated by LSAB
immunohistochemistry technique using anti-TNFR-II marker (polyclonal antibodies – Abcam
U.S.A. – clone ab15563-500, Rabbit polyclonal antihuman to TNF Receptor II). Histological
slides had about 5 μm thicknesses and were fixed on silanized slides (Dako) during 24 hours
in 37°C, followed by deparaffination in xylen. Antigen retriever had been made using a
pressurized cooker in citrate solution, pH=6.0 (Dako); endogenous peroxidase was inactivated
by peroxidase blocking reagent (Dako - Peroxidase blocking reagent 3%) during 5 minutes at
the room temperature. Primary monoclonal antibodies (anti-TNFR-II) were maintained
overnight, during 18 hours at 4°C, using a dilution of 1:50 in antibody diluent (Dako). The
visualization of immunological reaction was performed using Universal LSAB+Kit/HRP,
Rb/Mo/Goat (DAB+) system (Dako); the counterstaining was performed by Mayer
hematoxylin. To evaluate the antibody specificity was used negative control (replacing the
primary antibody with antibody diluent).
Microscopic examination and quantification. The microscopic images were obtained
by Olympus BX51 microscope, connected to a photo digital camera (Olympus DP-25).
TNFR-II quantification was realized by following cells with immunomarked membrane,
where the receptor is. Positive cells had a brown membrane of variable intensities. Counting
of TNFR-II positive cells had been made in about three high powered microscopic fields (400
folds magnification) for every studied tumor, being evaluated about 900-1300 cells/tumor.
There were monitored and elected microscopic fields with less connective sustentacular
tissue. In every monitored microscopic field were counted only epithelial and myoepithelial
cells, and weren’t counted positive stromal cells or inflammatory cells from tumoral stroma.
We used a semiautomatic computerized analysis technique (Olympus Soft imaging solutions
Cell B).
RESULTS AND DISCUSSIONS
In the Table 1 are presented the results obtained from every canine mammary tumor
taken in study, and these results will be debated later.
Tumor necrosis factor (TNF) is a proinflammatory cytokine that have an important
role in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis or
Crohn diseases in humans. TNF is found as a 26kd membrane bound molecule which, when
cleaved by the TNF converting enzyme (TACE), forms soluble TNF consisting of the 76
aminoterminal residues with a molecular weight of 17kd (Waterston Ashita et al., 2004).
Under native conditions bound and soluble TNF exist as a monomer, dimer and trimer in
equilibrium, with the trimer being the biologically active form. TNF belongs to the TNF
superfamily, which includes Lymphotoxin a and b, Fas ligand, CD40 ligand, and two
apoptosis inducing ligands, TRAIL/Apo-2 ligand (Waterston Ashita et al., 2004) and LIGHT,
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which is also involved in T cell activation (Mauri et al., 1998). These proteins are all ligands
for the TNF receptor superfamily.
Tab 1.
Summary of the results obtained by evaluation of studied canine mammary tumors.
Case
nr.
Tubular
structure
(grade)
NP
(grade) MI
Histopathologic
diagnose HG
TNFR-II (%)
Field 1 Field 2 Field 3 Average
1 - - - simple adenoma - 7,45 5,61 6,93 6,66
2 1 1 14
simple cystic
papillary
carcinoma
I 12,6 5,9 9,35 9,28
3 1 2 19 simple tubular
carcinoma I 5,55 4,88 2,39 4,24
4 2 2 12
complex tubule-
papillary
carcinoma
II 8,39 5,70 11,26 8,45
5 1 1 10
complex tubule-
papillary
carcinoma
I 7,98 4,40 5,93 6,10
6 2 2 14
complex tubule-
papillary
carcinoma
II 10,55 7,61 5,53 7,89
7 - - - simple adenoma - 7,87 7,86 5,83 7,18
8 1 3 16
simple tubule-
papillary
carcinoma
II 9,37 7,87 6,27 7,83
9 2 3 19
cystic papillary
cystic
carcinoma in
benign mixed
tumor
II 10,54 11,67 7,27 9,82
NP: nuclear polymorphism.
MI: mitotic index – number of mitoses/10 microscopic fields magnified of 400 folds.
HG: histologic grade.
TNFR-II (%): percentage value obtained by quantification of tumoral cells/3 microscopic fields magnified of
400 folds.
TNF binds with high affinity to two cell surface receptors, a 55kd protein (p55TNF-R
or TNFR-I) and a 75kd protein (p75TNF-R or TNFR-II), both are expressed by most cell lines
and primary tissues. However, the level of receptor expression varies with cell type. The
p55TNF-R expression is dominant on most cells, except for haemopoetic cells, and is
relatively constant, while the p75TNF-R expression fluctuates (Waterston Ashita et al., 2004).
It is thought that p55TNF-R is the major signal transducer of soluble TNF responses, due to
the abundance and binding avidity of this receptor; while p75TNF-R is preferentially
activated by membrane bound TNF (Grell et al., 1995; Smith et al., 1994).
The major sources of TNF are macrophages and to a lesser extent T lymphocytes,
proliferating B cells, natural killer (NK) cells, mast cells and stimulated neutrophils (English
et al., 1991; Gemlo et al., 1988; Gordon et al., 1990). Non-immune cells such as
keratinocytes, smooth muscle cells, astrocytes and microglial cells have all been shown to
produce TNF upon lipopolysaccharides stimulation in vitro (Kock et al., 1990; Waterston
Ashita et al., 2004). TNF is a pleiotropic cytokine, which acts on a large variety of cells with
wide ranging effects on individual cells. TNF promotes the pro-inflammatory cascade, by
inducing the release of pro-inflammatory cytokines such as the chemokine IL-8 (Nickoloff et
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al., 1991), IL-6 (Waterston Ashita et al., 2004), and adhesion molecules such as VCAM
important in metastasis (Osborn et al., 1990).
TNF in large quantities may lead to tumor necrosis, antitumor effects being a
consequence of vascular induced tumor necrosis, or the consequence of apoptosis initiation by
activating caspases 8 and 10, or finally the consequence of direct cytotoxic effects induced by
free radicals and lysosomal enzymes (Enari et al., 1998; Waterston Ashita et al., 2004).
The studies that investigated the effects of these cytokines are diverse and
controversial. Also, it had been proved antitumor effect of TNF in combination with some
other cytokines or chimiotherapeutic agents, aspects observed in oncologic clinic in some
sarcomas and melanomas (Waterston Ashita et al., 2004). On the other hand, despite of the
name it seems that TNF can act as pro-carcinogenic agent favoring tumor onset and
subsequent cancerous progression, tumor associated cahexy being the consequence of
proteolysis and lipids metabolization (Aggarwal et al., 2003; Balkwill et al., 2006; Mocellin
et al., 2008). Concluding, it seems that TNF can act not only as anti-cancerous agent but as
pro-carcinogenic agent initiating and favoring tumor progression especially in aged animals.
Furthermore, in experimental models of cancer induction realized in rats TNF favor not only
the metastasis but intratumor angiogenesis as well. These strong pro-cancerous effects could
be the consequence of deregulation of TNF production such as overproduction of this
cytokine (Balkwill et al., 1992).
The mechanism and signalling events associated with carcinogenesis are still being
elucidated. TNF, along with other proinflammatory cytokines, induces nitric oxide synthetase
in a cholangiocarcinoma cell line. This enzyme produces nitric oxide, which can increase
DNA damage by inhibiting sensitive DNA repair enzymes, and thereby contributes to an
increase in genetic mutations (Jaiswal et al., 2000). Other studies have shown that the
presence of iNOS in gynecological tumours correlates with dedifferentiation (Waterston
Ashita et al., 2004). Therefore, the production of nitric oxide through TNF induction of iNOS
may not only lead to tumour cell apoptosis, as described previously, but may also promote
carcinogenesis. The signalling pathways induced by TNF have also been examined in rat
mammary cells. TNF stimulated growth and morphogenesis of normal rat mammary epithelial
cells as well as transformed mammary epithelial tumours. TNF may induce carcinogenesis by
up-regulating of some proteins (NF-kB) that cause cell proliferation and morphogenesis
(Waterston Ashita et al., 2004).
Further, the TNF seems to have an important role as well in metastasis. TNF is a
potent proinflammatory cytokine that can be utilized by tumours to induce some downstream
molecules involved in the metastatic process. Recombinant TNF injected into mice inoculated
with a methylcholanthrene-induced fibrosarcoma increased the number of lung metastases
(Orosz et al., 1993).
Regarding the TNF involvement in tumor neovascularisation and angiogenesis, it was
shown that some chemokines such as IL-8 and Groα as well as other growth factors e.g. FGF,
PDGF and thymidine phosphorylase are important in neovascularisation (Nagy et al., 1995;
Waterston Ashita et al., 2004). They attract endothelial cells and cause the migration of
capillaries into the tumours. TNF has been found to increase the expression of IL-8 and Groα
in a number of different cell types (Strieter et al., 1995). In histological samples of malignant
breast cancer, increased TNF staining correlated with increased thymidine phosphorylase an
important enzyme in angiogenesis (Waterston Ashita et al., 2004).
Having these paradoxes about TNF activities in different tumor types, this study will
show some aspects regarding TNFR-II in canine spontaneous mammary cancer. Obtained
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dates will be compared with some classic parameters for this type of tumor, such as histologic
type, and histologic grade (grades I to III).
Our dates was realized on mammary tumors provided by bitches of different ages (2-
13 years old) and breeds, respectively German Sheppard, Cocker Spaniel, stray dogs (every
one about 22,20% from examined cases), Mioritic Sheppard, Boxer and  Irish Setter (every
one about 11,10% from examined cases) (Table 1). In the study were elected benign and
malign canine mammary tumors, such as: two simple adenomas (22,2% from all tumors),
three complex tubulopapillary carcinomas (33,3% from all tumors), two simple tubule-
papillary carcinomas (22,2% from all tumors), one simple cystic carcinoma (11,1% from all
tumors), and one carcinoma in benign mixed tumor (11,1% from all tumors). Malign tumors
were framed in histological grades for a better understanding of their malignancies, such as:
three grade I mammary tumors (cases 2, 3, 5) and four grade II mammary tumors (cases 4, 6,
8, 9).
Concerning localization and distribution of TNF cytokine 2-nd receptor, particularly
of TNFR-II, it was encountered in both inflammatory cells from the sustaining stroma of
studied tumors (macrophage, lymphocyte – Fig. 2 and 4), and in cancerous epithelial or
myoepithelial cells (Fig. 1). There was an increased incidence of TNFR-II especially in
cancerous cells placed circa intra-tumoral necrotized areas indicating, probably, it’s
involvement in induction of tumoral apoptosis and necrosis. The tumors with tubular
cancerous structures had numerous intraductal TNFR-II positive desquamated cells indicating
apoptosis (Fig 3). In fact it is known from bibliographic dates mentioned earlier that TNF
cytokine can induce intratumor necrosis, this ability being utilized by some therapeutic
antitumor protocols (Waterston Ashita et al., 2004). On the other hand, the presence of
TNFR-II in inflammatory cells from tumoral sustaining stroma could indicate TNF potential
in cancer developments, progression and metastasis, aspects highlighted as well in the
literature (Mocellin et al., 2008; Waterston Ashita et al., 2004). Deregulated TNF expression
within the tumor microenvironment appears to favor malignant cell tissue invasion, migration
and ultimately metastasis formation. TNF clearly possesses antitumor effects not only in
preclinical models but also in the clinical setting. These conflicting findings and apparently
paradoxical TNF activities, such as anticancer as well as cancer-promoting TNF effects, are
realties observed in clinical and animal models being quite dificult to explain the coexistence
of these (Aggarwal et al., 2003; Balkwill et al., 2006; Waterston Ashita et al., 2004).
Fig. 1. Complex tubule-papillary carcinoma, case 4 – tubular structures with immunomarked tumoral cells
(arrows); IHC reaction anti-TNFR-II, 400x.
Fig. 2. Complex tubule-papillary carcinoma, case 4 – expression of TNF 2-nd receptor in inflammatory cells
from sustaining stroma (macrophages); IHC reaction anti-TNFR-II, 100x.
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Fig. 3. Complex tubule-papillary carcinoma, case 6 – tumoral ductal structures with dequamated (apoptotic) and
immunomarked cancerous cells (arrow); IHC reaction anti-TNFR-II, 400x.
Fig. 4. Simple tubule-papillary carcinoma, case 8 – TNFR-II immunopositive macrophages in tumoral capsule;
IHC reaction anti-TNFR-II, 200x.
Distribution of TNFR-II in cancerous mammary cells and correlation between its
incidence with histologic grade can be observed in figure 5. There is obvious a direct
relationship between the two parameters. Also, benign tumors and differentiated mammary
carcinomas have the fewest TNFR-II immunomarked tumoral cells (values ranging from
4,24% to 9,28%) comparing with poorly differentiated canine mammary carcinomas (grade
II) where TNFR-II incidence had greater values (values ranging from 7,83% to 9,82%). The
only difference is represented by the case 2, which despite being a differentiated one have
high percentage of cells with TNFR-II (TNFR-II positive cells - 9,28%).
Figure 5. Correlation between histologic grade and average percentage value of TNFR-II.
Obtained dates regarding TNFR-II deliver some additional important data regarding
intratumor distribution in different types of benign and malign canine mammary tumors. The
bibliographic dates is poor in information about intratumor distribution and role of the 2-nd
receptor of TNF-α cytokine (TNFR-II or p75 TNFR). There is a high amount of information
about the first receptor of TNF-α (TNFR-I or p55 TNFR). We will present some bibliographic
data concerning distribution, role and significance of the TNFR-I in different tumor types.
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TNF has been detected in a number of different tumour types such as ovarian and breast tissue
as well as haematological malignancies (Miles et al., 1994; Naylor et al., 1993; Warzocha et
al., 2000). Both mRNA expression and TNF protein has been found in human epithelial
ovarian tumour cells as well as within the infiltrating macrophages. The p55 TNFR has also
been detected within ovarian tumour cells and infiltrating macrophages but not stromal
macrophages whilst the p75 TNFR has only been found within the infiltrating macrophages
(Naylor et al., 1993). Compared to ovarian human tumors, actual study proved that p75 TNFR
(TNFR-II) was expresses within mammary tumoral cells (cancerous epithelial and
myoepithelial cells) and in infiltrating stromal inflammatory cells. There was observed a
direct relation between malignancy and expression of TNFR-II. Also, histologic grade and
especially proliferating marker Ki-67 values increased in the same time with expression of
TNFR-II. According to this, overexpression of TNFR-II can be correlated with a poor
prognosis and high malignancy degree in the case of canine mammary cancer. A similar
picture of increased production of TNF correlating with worse prognosis has been identified
in patients with prostrate cancer. In these patients, raised serum TNF levels were associated
with a reduction in body mass index and other factors associated with cachexia as well as a
significantly increased mortality (Nakashima et al., 1998; Mizokami et al., 2000).
CONCLUSIONS
Distribution and localization of TNFR-II was restricted in both inflammatory cells
from the sustaining stroma of studied tumors (macrophages, lymphocytes), and in cancerous
epithelial or myoepithelial cells.
There was an increased incidence of TNFR-II especially in cancerous cells placed
circa intratumoral necrotized areas and in desquamated intraductal tumoral cells indicating
TNFR-II involvement in induction of tumoral apoptosis and necrosis.
Obtained dates demonstrate a direct relation between histologic grade and TNFR-II
expression in cancerous epithelial and myoepithelial cells; TNFR-II had a lower expression in
benign and differentiated grade I canine mammary tumors, and a higher expression in poorly
differentiated ones (grade II cancers).
The study demonstrate, comparing with bibliographic dates, that TNFR-II can be met
not only in the inflammatory cells of the canine mammary carcinoma but as well in cancerous
mammary tumors (epithelial and myoepithelial cancerous cells).
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